Filter your results
- 3
- 3
- 3
- 1
- 2
- 3
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL groupCancer, 2015, 121 (14), pp.2393-2399. ⟨10.1002/cncr.29389⟩
Journal articles
hal-01237097v1
|
||
Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03) / 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FLBlood, 2015, 126 (23), pp.3028
Journal articles
hal-01290431v1
|
|||
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myelomaLeukemia, 2022, 36 (3), pp.881-884. ⟨10.1038/s41375-021-01415-x⟩
Journal articles
hal-03476700v1
|